Regenxbio unveils positive data from diabetic retinopathy therapy trial

RegenxBio has unveiled positive one-year data from the Phase II ALTITUDE trial of ABBV-RGX-314 to treat diabetic retinopathy (DR) without center-involved diabetic macular oedema (CI-DME) using in-office suprachoroidal delivery.